Bio-Techne: ExoDx Prostate Test granted expanded coverage by Medicare

Bio-Techne announced that a newly finalized local coverage determination from National Government Services, a Medicare Administrative Contractor, includes coverage for the ExoDx Prostate Test from Exosome Diagnostics, a Bio-Techne brand. The updated policy now covers an annual ExoDx Prostate Test for men who already had a negative biopsy but are thought to be at high risk for prostate cancer and are considering a repeat biopsy. The coverage will go into effect March 1, 2023.